IN8BIO Inc., a clinical-stage biopharmaceutical company, reported its financial results for the first quarter ending March 31, 2025. The company recorded a net loss of $5.6 million, or $0.07 per common share, an improvement from the net loss of $8.6 million, or $0.20 per share, in the same period the previous year. General and administrative expenses decreased to $2.7 million from $3.7 million, attributed to cost savings in personnel, insurance premiums, and professional services. The company's cash position was $11.9 million as of March 31, 2025, slightly down from $13.0 million in the previous year. In April 2025, IN8BIO raised additional gross proceeds of $1.9 million. On the operational front, IN8BIO continued to make strides in its gamma-delta T cell therapies. The Phase 1 clinical data for INB-100 showed promising long-term remission results in Acute Myeloid Leukemia patients, with all remaining relapse-free at a median follow-up of 20.1 months. The company also presented new data on its INB-600 platform at the American Association for Cancer Research 2025 Annual Meeting, highlighting potential applications in oncology and autoimmune diseases. Upcoming milestones include an oral presentation of INB-200 at the American Society of Clinical Oncology 2025 Annual Meeting.